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Abstract
Background: Genetic susceptibility to type 2 diabetes (T2D) is multifactorial. A growing number of genes have
been identified as risk factors for T2D across multiple ethnicities in trans-ancestry meta-analysis of large-scale
genome-wide association studies. Few studies have looked at these genes in Sub-Saharan African populations. This
study was undertaken to look for associations between T2D and single nucleotide polymorphisms (SNPs) in a
number of the top candidate genes in a selected Sudanese population.
Methods: A total 240 T2D cases and 128 unrelated healthy control subjects were included in this study. Age, sex,
weight and height were recorded, blood pressure and biochemical profiles of glucose and lipids were analysed.
Single nucleotide polymorphism (SNP) genotyping was performed using the Sequenom MassARRAY® system. Fourteen
SNPs were selected across 7 genes: CAPN10 (rs2975760 and rs5030952), PPARG (rs17036314 and rs1801282), IGF2BP2
(rs4402960 and rs1470579), CDKAL1 (rs9465871), HHEX (rs1111875), TCF7L2 (rs7903146, rs11196205 and rs12255372),
and KCNJ11 (rs5215, rs1800467 and rs5219). Allelic and haplotype association analyses were performed under additive
models in PLINK. P≤ 0.007 (=0.05/7 genes) was the P-value required to achieve correction for multiple testing.
Results: A significant genetic association between the SNPs rs7903146 (odds ratio 1.69, 95 % confidence interval
1.21–2.38, P = 0.002) and rs12255372 (odds ratio 1.70, 95 % confidence interval 1.20–2.41, P = 0.003) at TCF7L2 and T2D
was found in Sudanese population. These associations were retained after adjusting for age, sex and BMI (e.g. rs7903146:
odds ratio 1.70, Padj:age/sex/BMI = 0.005). The strongest haplotype association (odds ratio 2.24; Padj:age/sex/BMI = 0.0003)
comprised the two point haplotype T_C across rs7903146 and rs11196205. Stepwise logistic regression demonstrated that
SNP rs7903146 added significant main effects to rs11196205 or rs12255372, whereas the reverse was not true, indicating
that the main effect for association with T2D in this population is most strongly tagged by SNP rs7903146. Adjusted
analyses also provided support for protection from T2D associated with minor alleles at SNPs rs2975760 at CAPN10
(odds ratio 0.44, 95 % confidence interval 0.20-0.97, Padj:age/sex/BMI = 0.042) and rs1111876 at HHEX (odds ratio 0.60, 95 %
confidence interval 0.39- 0.93, Padj:age/sex/BMI = 0.022).
Conclusions: Multiethnic associations between T2D and SNPs at TCF7L2, CAPN10 and HHEX extend to Sub-Saharan Africa,
specifically Sudan.
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Background
Type 2 diabetes (T2D) is emerging as an important
international health problem. The International Diabetes
Federation (IDF) report that 382 million people world-
wide are living with diabetes, with a further 316 million
with impaired glucose tolerance and therefore at high
risk from the disease [1]. Evidence published in the IDF
Diabetes Atlas [1] disproves the misconception that dia-
betes is a disease of the wealthy. Indeed, more than 80 %
of people with diabetes live in low and middle-income
countries, with emerging hotspots including countries in
the Middle East and Sub-Saharan Africa [1]. In Sudan,
Awad et al. [2] reported a prevalence of 3.4 % and consid-
ered diabetes as the commonest cause of hospital admis-
sion and morbidity due to a non- communicable disease.
The highest prevalence is reported in northern Sudan [3]
and the lowest in the western desert regions [4], with data
reported in the IDF Diabetes Atlas [1] suggesting preva-
lence varying from 6-10 % and 60 % of deaths due to dia-
betes occurring in people under 60 years of age.
Since the introduction of genome-wide association
studies (GWAS) a large number of genes have been
shown to be associated with T2D at genome-wide signifi-
cance (generally accepted to be P ≤ 5x10−8 [5]), including
many that have been shown to have effects across multiple
ethnicities [6–19] and in trans-ancestry meta-analysis of
large-scale GWAS [20]. Only a few studies have looked at
these genes in Arab [16, 18, 19, 21–23] or Sub-Saharan
African populations [8, 17]. In this study we looked for as-
sociation between 14 single nucleotide polymorphisms
(SNPs) in 7 of the top GWAS genes (TCF7L2, CDKAL1,
HHEX, IGF2BP2, KCNJ11, PPARG and CAPN10) and risk
of T2D in Sudan.
Methods
Study area and population
The study was approved by the ethics committee of
Institute of Endemic Diseases, University of Khartoum.
Written informed consent was obtained from all cases
and controls, all of whom were from the population of
Tuti Island, Khartoum, Sudan descended from one large
family from the Mahas tribe of northern Sudan. Ascer-
tainment of cases was by identification of patients at-
tending Tuti Health Centres for monthly follow up.
Individuals were classified as having T2D when they met
all of the following criteria: (1) diagnosed with T2D by a
qualified physician; (2) on a prescribed drug treatment
regimen for T2D; and (3) returned biochemical test results
of a fasting plasma glucose level of at least 126 mg/dl
(=7 mmol/l in SI units) based on the criteria laid by the
World Health Organisation [24]. Healthy controls were
selected from the general population of Tuti Island. All
participants were consented for blood by venipuncture for
DNA and biochemical tests (cf. below), and for recording
of height and weight to determine body mass index
(BMI). All participants answered a questionnaire approved
by the ethics committee, and designed to collect socioeco-
nomic data, as well as, age, sex, family history of diabetes
and diagnosis.
Lipid profile and glucose measurement
Blood samples were obtained in Fluoride Oxalate and
EDTA tubes from all participants after an overnight
(8-12-h) fast. Plasma was used for the determination
of glucose, total cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL) and triglyceride
(TG). All of these parameters were measured using
spectrophotometry (Spectrum lab 22PC).
DNA extraction and SNPs genotyping
The guanidine chloride-chloroform method was used for
DNA extraction. SNP genotyping was carried out at
Shanghai Benegene Biotechnology Co., Ltd (Shanghai,
China) using the Sequenom MassARRAY® system. A
total of 14 SNPs was selected for genotyping across 7
genes: CAPN10 (rs2975760 and rs5030952), PPARG
(rs17036314 and rs1801282), IGF2BP2 (rs4402960 and
rs1470579), CDKAL1 (rs9465871), HHEX (rs1111875),
TCF7L2 (rs7903146, rs11196205 and rs12255372,), and
KCNJ11 (rs5215, rs1800467 and rs5219). SNP selection
was based on top SNPs reported from a number of
published candidate gene, GWAS or replication studies
[8, 9, 12, 20, 25–29].
Statistical analysis
Statistical comparisons of demographic (age, sex) and
quantitative clinical variables (systolic blood pressure,
diastolic blood pressure, BMI, fasting glucose, total chol-
esterol, HDL, LDL, and TG) between cases and controls
were analysed in Prism5 using T- tests with Welch’s cor-
rection for unequal variances when applicable. All SNPs
were tested for Hardy-Weinberg equilibrium. Linkage dis-
equilibrium (r2 and D') between SNPs was determined
using Haploview 4.1. Analyses to determine associations
between SNPs and T2D were performed under additive,
dominant and recessive models using logistic regression
within PLINK [30] (http://pngu.mgh.harvard.edu/purcell/
plink), with/without adjustment for age, sex and BMI as
indicated. Only data for the additive model are provided
here as in every case this model was adequate to explain
the associations observed. Haplotype analyses were also
performed within PLINK.
Results
Demographic and clinical profile of cases and controls
Demographic, clinical and biochemical parameters for
225 T2D cases (age range 20 to 89 years) and 129
healthy controls (age range 20 to 85 years) originally
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recruited into the study are presented in Table 1. As ex-
pected, significant differences in clinical traits associated
with T2D (systolic blood pressure, fasting glucose, and total
cholesterol) were observed between cases and controls. Age
and BMI also differed between cases and controls. Since
age, sex and BMI are known to be independent risk factors
for T2D [1], we adjusted for these in our genetic analyses
looking for associations between SNPs and T2D. A total of
186 cases and 106 controls with complete records for age,
sex, and BMI were taken forward in these adjusted associ-
ation analyses as presented below.
Characteristic of SNPs in the study population
All SNPs were in Hardy-Weinberg equilibrium in the con-
trol sample (p > 0.05). Minor allele frequencies (MAF) for
SNPs are provided in Table 2, and compared with MAF
for Hapmap populations. Two SNPs, PPARG rs1801282
and KCNJ11 rs1800467, were at MAF < 0.05 in our popu-
lation and were removed from the association analyses.
These low MAFs were consistent with low MAFs for these
SNPs in all three HapMap populations. The remaining 12
SNPs were taken forward in the association analyses. The
strict P-value needed to achieve statistical significance tak-
ing multiple testing into account is P = 0.004 (=0.05/12).
However, this is conservative since multiple SNPs within
genes showed some degree of linkage disequilibrium, as
might be expected given that they were selected as top
SNPs for association with T2D in other populations.
Therefore, P ≤ 0.007 (=0.05/7 genes) was used as the
P-value required to achieve correction for multiple testing.
Allelic association between candidate gene SNPs and T2D
in Sudan
DNA was available for genotyping from 190 cases and 129
controls. Table 3 provides results of logistic regression
analyses to test for allelic associations between SNPs at
candidate genes and T2D. In the unadjusted analysis that
included all study participants with DNA available
(Table 3: Column entitled Unadjusted All) two SNPs at
TCF7L2, rs7903146 (odds ratio 1.69, 95 % confidence in-
tervals 1.21-2.38, P = 0.002) and rs12255372 (odds ratio
1.70, 95 % confidence intervals 1.20-2.41, P = 0.003),
achieved P-values that withstand correction for multiple
testing (P < 0.007). In the reduced data set that comprised
individuals with complete data for age, sex, and BMI, the
three SNPs at TCF7L2 achieved nominal P < 0.05 (Table 3:
Column entitled Unadjusted). Of the three SNPs, signifi-
cance at TCF7L2 rs7903146 achieved P < 0.007 following
adjustment for age, or age and sex. This was retained after
additionally adjusting for BMI, suggesting that this is a
gene for T2D and not the result of confounding due to
the strong correlation between BMI and T2D [1]. SNPs
rs2975760 at CAPN10 and rs1111875 at HHEX also
achieved nominal P < 0.05 after adjustments for age with/
without additional adjustments for sex, or sex and BMI.
Haplotype associations and stepwise logistic regression
analysis for SNPs at TCF7L2
Since all three SNPs at TCF7L2 were associated with
T2D in our population, the question arises as to whether
all SNPs were tagging a single functional variant, or
whether multiple main effects occur. SNPs within
TCF7L2 were in strong linkage disequilibrium as deter-
mined by D' (rs7903146 and rs11196205: D' = 0.94;
rs7903146 to rs12255372: D' = 0.68; rs11196205 to
rs12255372: D' = 0.80), suggesting that all 3 SNPs may
be tagging a single haplotype carrying the risk variant.
This was not so strongly supported by linkage disequi-
librium as determined by r2 (rs7903146 and rs11196205:
r2 = 0.36; rs7903146 to rs12255372: r2 = 0.35; rs11196205
to rs12255372: r2 = 0.23) which takes allele frequencies
into account. It was of interest too that the minor allele
at rs11196205 was associated with protection, whereas
for the other two TCF7L2 SNPs the minor alleles were
the risk alleles. We therefore carried out haplotype asso-
ciation analyses to see where the strongest associated
haplotypes occur. As before (Table 3), the strongest sin-
gle point association was at rs7903146 (odds ratio 1.70;
Padj:age/sex/BMI = 0.005). Notably, the associated (odds
ratio >1) two point and three point risk haplotypes were
on the background of the common C allele at
rs11196205 (Table 4), with the strongest association
(odds ratio 2.24; Padj:age/sex/BMI = 0.0003) comprising the
two point haplotype T_C across rs7903146 and
rs11196205. In a stepwise logistic regression analysis
(Table 5), SNP rs7903146 added significant main effects
to rs11196205, whereas the reverse was not true. Simi-
larly, whilst rs7903146 added significant main effects to
rs12255372, the reverse was not true. Together these
Table 1 Clinical and biochemical parameters of type 2 diabetes
cases and controls
Trait Controls Cases T testa
Mean ± SD (n) Mean ± SD (n) P-value
Age (years) 48 ± 15 (118) 58 ± 13 (225) <0.001*
Systolic BP (mmHg) 122 ± 18 (104) 132 ± 22 (202) <0.001*
Diastolic BP (mmHg) 75 ± 13 (105) 77 ± 15 (204) 0.231
BMI (kg/m2) 27 ± 6 (107) 29 ± 7 (234) 0.017
Fasting glucose (mg/dl) 105 ± 32 (66) 155 ± 58 (124) <0.001*
Cholesterol (mg/dl) 198 ± 72 (67) 171 ± 63 (125) 0.012
HDL (mg/dl) 76 ± 43 (59) 69 ± 43 (115) 0.287
LDL (mg/dl) 115 ± 58 (47) 104 ± 60 (95) 0.281
TG (mg/dl) 129 ± 75 (66) 105 ± 68 (125) 0.026
aT-Test with Welch’s correction for unequal variance where applicable;
*indicates unequal variances. SD = Standard Deviation, n = number of the
samples, BP = Blood pressure, BMI = Body Mass Index, HDL = High Density
Lipoprotein, LDL = Low Density Lipoproptein, TG = Triglyceride
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results are consistent with a single main effect for asso-
ciation with T2D in this population that is most strongly
tagged by SNP rs7903146.
Discussion
In the present study, we investigated a possible associ-
ation between T2D in Sudan and SNPs from 6 genes
(PPARG, IGF2BP2, CDKAL1, HHEX, TCF7L2, and
KCNJ11) that had achieved genome-wide significance in
multiple GWAS undertaken across different ethnicities
[31], in addition to CAPN10 which had been shown to
be associated with T2D in a large study of Caucasians
[26] and in Tunisia [27]. Of these, we found significant
evidence for association between T2D and SNPs at
TCF7L2 in our Sudanese population, and suggestive evi-
dence for associations at SNPs in CAPN10 and HHEX.
Given the limitations of our sample size, we cannot dis-
count the possibility that further associations with SNPs
in more of these genes would be found in this popula-
tion if larger sample sizes were employed. However, rela-
tively few studies have determined the role of common
global T2D associated genetic variants in Sub-Saharan
Africa, and to our knowledge this is the first study to
provide evidence for associations between T2D and
these important diabetes genes in a Sudanese popula-
tion. Thus our study contributes to the growing need to
replicate associations observed in GWAS carried out
predominantly in Caucasian populations.
CAPN10 is of some interest as the first T2D gene to
have been identified in a genome wide linkage scan [32],
followed by positional cloning [33]. Subsequent large-
scale meta-analysis of 13,628 subjects found only a modest
effect size (odds ratio 1.15; 95 % confidence intervals 1.07-
1.23; P = 0.0002) for allele T at SNP rs2975760 as a risk fac-
tor for T2D [26], and no GWAS have reported P < 1x10−5
for association between T2D and CAPN10 as currently re-
corded in the NCBI Catalog of published GWAS [31].
Some evidence for associations with larger effect sizes (odds
ratios 1.35 to 1.61) were recently reported for SNPs at
CAPN10 and risk of T2D in a Tunisian Arab population
[27]. Here we show that the T allele at SNP rs2975760 was
also associated with a larger effect size (odds ratio 2.38;
95 % confidence interval 1.09-5.26; P = 0.03) in the Sudan-
ese study population following adjustment for age. Further
work is required to determine whether this is indicative of
population-specific roles for polymorphisms at CAPN10 as
risk factors for T2D in African populations.
The association at HHEX is also of interest given prior
strong candidacy of this gene as a risk factor for T2D in
multiple other populations [8, 9, 20], in this case well
supported by results of multiple GWAS including trans-
ancestry studies recorded in the NCBI Catalog of pub-
lished GWAS [31]. HHEX belongs to a large family of
transcription factors that are distinguished by a 60
amino acid conserved DNA-binding homeodomain. It is
expressed in the anterior visceral endoderm during early
development and in some adult tissues of endodermal
origin, including liver and thyroid. In humans HHEX is
associated with decreased insulin secretion in response
to oral glucose stimulation, while knockout mouse stud-
ies demonstrate that the gene is a regulator of glucose-
stimulated insulin secretion [34]. HHEX is located in a
Table 2 Details of SNPs used in this study
Gene Chr SNP bp Location GRCh38 Minor Allele MAF SDNa MAF HapMap Populations
N = 129 CEU HCB YRI
CAPN10 2 rs2975760 240591746 C 0.07 0.16 0.11 0.01
rs5030952 240603286 T 0.35 0.05 0.26 0.63
PPARG 3 rs17036314 12335246 C 0.26 0.20 0.22 0.18
rs1801282 12351626 G 0.02 0.08 0.02 0
IGF2BP2 3 rs4402960 185793899 G 0.46 0.72 0.78 0.46
rs1470579 185811292 A 0.28 0.72 0.74 0.13
CDKAL1 6 rs9465871 20717024 C 0.34 0.16 0.48 0.61
HHEX 10 rs1111875 92703125 A 0.25 0.42 0.69 0.13
TCF7L2 10 rs7903146 112998590 T 0.30 0.28 0.02 0.26
rs11196205 113047288 G 0.48 0.58 0.96 0.14
rs12255372 113049143 T 0.24 0.22 0 0.27
KCNJ11 11 rs5215 17387083 C 0.13 0.39 0.35 0.01
rs1800467 17387284 G 0.03 0.05 0 0.01
rs5219 17388025 T 0.08 0.39 0.39 0
aMAF – minor allele frequency for Sudan (SDN) healthy controls
Details include minor allele frequencies (MAF) in control subjects (N = 129) from the Sudanese (SDN) study compared with CEU, HCB and YRI HapMap populations.
Chr = chromosome; bp Location = chromosomal base pair location of the SNP in Genome Reference Consortium Human Build 38 (GRCh38)
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Table 3 Association between SNPs and T2D in the Sudan study population
Chr Gene SNP bp
Location
A1 N Unadjusted All N Unadjusted Adj Age Adj Age, Sex Adj Age, Sex, BMI
OR L95 U95 P OR L95 U95 P OR L95 U95 P OR L95 U95 P OR L95 U95 P
2 CAPN10 rs2975760 241531413 C 317 0.62 0.31 1.24 0.175 259 0.52 0.25 1.07 0.074 0.42 0.19 0.92 0.030 0.44 0.20 0.96 0.040 0.44 0.20 0.97 0.042
2 CAPN10 rs5030952 241542953 T 314 0.80 0.57 1.12 0.197 257 0.78 0.54 1.15 0.208 0.82 0.55 1.21 0.314 0.80 0.54 1.20 0.280 0.80 0.54 1.19 0.274
3 PPARG rs17036314 12376995 C 300 0.96 0.67 1.38 0.824 242 1.12 0.74 1.71 0.596 1.18 0.75 1.84 0.474 1.14 0.73 1.78 0.558 1.16 0.74 1.81 0.517
3 IGF2BP2 rs4402960 185511937 G 317 0.86 0.63 1.18 0.349 260 0.93 0.66 1.31 0.684 0.93 0.65 1.33 0.693 0.95 0.66 1.35 0.767 0.95 0.66 1.36 0.777
3 IGF2BP2 rs1470579 185529330 A 316 1.01 0.72 1.42 0.959 258 1.02 0.70 1.49 0.924 0.99 0.66 1.46 0.941 1.00 0.68 1.49 0.986 1.02 0.68 1.51 0.930
6 CDKAL1 rs9465871 20717505 C 315 1.27 0.94 1.73 0.120 257 1.17 0.83 1.65 0.376 1.15 0.81 1.65 0.432 1.15 0.80 1.65 0.456 1.15 0.80 1.66 0.443
10 HHEX rs1111875 94463132 A 319 0.71 0.50 1.01 0.060 261 0.68 0.45 1.02 0.060 0.61 0.40 0.94 0.026 0.61 0.40 0.95 0.027 0.60 0.39 0.93 0.022
10 TCF7L2 rs7903146 114758599 T 301 1.69 1.21 2.38 0.002 245 1.62 1.11 2.37 0.013 1.75 1.18 2.61 0.006 1.81 1.21 2.70 0.004 1.79 1.20 2.67 0.005
10 TCF7L2 rs11196205 114807297 G 306 0.78 0.58 1.06 0.117 248 0.68 0.48 0.96 0.029 0.63 0.44 0.91 0.013 0.64 0.44 0.92 0.017 0.64 0.44 0.93 0.018
10 TCF7L2 rs12255372 114809152 T 319 1.70 1.20 2.41 0.003 261 1.53 1.04 2.25 0.031 1.57 1.06 2.33 0.026 1.58 1.07 2.35 0.023 1.60 1.08 2.38 0.021
11 KCNJ11 rs5215 17408880 C 315 1.13 0.69 1.85 0.622 257 0.96 0.56 1.63 0.877 1.02 0.59 1.77 0.944 1.05 0.60 1.84 0.852 1.04 0.60 1.82 0.881
11 KCNJ11 rs5219 17409822 T 316 1.24 0.71 2.16 0.452 258 1.11 0.60 2.06 0.735 1.25 0.66 2.37 0.500 1.31 0.68 2.51 0.419 1.27 0.66 2.45 0.468
Data are presented for an unadjusted analysis for all participants in the study, and for unadjusted and adjusted (as indicated) analyses performed in the subset of individuals for whom complete data on age, sex and
BMI was available. Chr = chromosome; bp Location indicates the chromosomal base pair location of the SNP in Genome Reference Consortium Human Build 38 (GRCh38); OR = odds ratio; L95 and U95 indicate lower
















region of chromosome 10 that harbors several genes in-
volved in beta-cell function or development, including
the TCF7L2 gene. However, the two genes are located
some 10 Mb apart, and their effects were independent in
our study.
Associations observed between polymorphisms at
TCF7L2 and T2D were the most strongly supported in our
Sudanese study population. This is in keeping with GWAS
and replication studies providing evidence for a role for this
gene as a risk factor for T2D across multiple ethnicities
[10–12, 14, 20, 31, 35], including a growing number of
studies in African Americans [15], Sub-Saharan African
[8, 17, 36] and Arab [16, 19, 21, 23, 25, 37–39] popula-
tions. Indeed, TCF7L2 was once described as the big-
gest story in diabetes since HLA [40]. Exceptions
include studies in Pima Indians [41] and an Australian
Aboriginal population [42]. This may relate to sample
size, and/or to the observation across several studies
that TCF7L2 variants are associated with reduced BMI
in diabetes cases (but not in controls) [40]. Hence, in a
population where T2D is predominantly associated with
high BMI, the association with TCF7L2 might not be so
readily observed. In Emiratis, for example, association
between TCF7L2 and T2D was only observed in a non-
obese case group and not in obese diabetics [38]. In our
Sudanese study, our sample size was too small to strat-
ify by BMI, but our association between TCF7L2 vari-
ants and T2D was robust to adjustment for BMI.
TCF7L2 encodes a high-mobility group box-containing
transcription factor. Collective evidence (reviewed [43])
supports the hypothesis that WNT/β-catenin signaling via
TCF7L2 regulates Glucagon-like peptide 1 effects in pan-
creatic β-cells by transcriptionally regulating its receptor.
In humans, the risk T allele at rs7903146 (the SNP most
strongly associated with T2D in our Sudanese population)
strongly predicted future T2D in two independent co-
horts, and was associated with impaired insulin secretion,
incretin effects, and an enhanced rate of hepatic glucose
production [44]. TCF7L2 expression in human islets was
increased 5-fold in T2D, particularly in carriers of the TT
genotype. Overexpression of TCF7L2 in human islets re-
duced glucose-stimulated insulin secretion. These authors
conclude that the increased risk of T2D conferred by vari-
ants in TCF7L2 involves the enteroinsular axis, enhanced
expression of the gene in islets, and impaired insulin se-
cretion [44].
Conclusions
In this study we found significant evidence for association
between T2D and SNPs at TCF7L2 in our Sudanese popu-
lation, and suggestive evidence for associations at SNPs in
CAPN10 and HHEX. The latter require confirmation in
studies of larger sample sizes in Sudan, and we cannot ex-
clude the possibility of associations with other genes ex-
amined here. Given its strong global associations with
T2D, the demonstration of association between TCF7L2
and T2D in this Sudanese population is important. The
cumulative evidence for associations between TCF7L2
polymorphisms across multiple ethnicities, together with
growing knowledge of WNT/TCF7L2 signaling in β-cells,
make it an attractive target for development of novel ther-
apies for diabetes [43]. Our research demonstrates that
T2D patients in Sudan would likely benefit from this
translation of genetic research to the clinic.
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Table 4 The effects of multiple SNPs at TCF7L2 on T2D risk in
the Sudanese population
Allele/Haplotype Frequency rs7903146 rs11196205 rs12255372
T 0.398 OR = 1.79;
P = 0.005
C 0.567 OR = 1.56;
P = 0.018
T 0.33 OR = 1.60;
P = 0.021
TC 0.377 OR = 2.24; P = 0.0003
CT 0.294 OR = 1.86; P = 0.005
TCT 0.236 OR = 1.86; P = 0.010
Analysis undertaken under an additive logistic regression model (adjusted for
age, sex, and BMI) to look for associations between haplotypes for the 3 SNPs
at TCF7L2 and risk of T2D in the Sudanese population. Bold indicates the most
significant haplotype association
Table 5 The effects of multiple SNPs at TCF7L2 on T2D risk in
the Sudanese population
Null model Alternative model OR P-value
rs7903146 rs7903146 + rs11196205 0.98 0.938
rs7903146 rs7903146 + rs12255372 1.22 0.437
rs11196205 rs11196205 + rs7903146 2.04 0.010
rs11196205 rs11196205 + rs12255372 1.53 0.078
rs12255372 rs12255372 + rs7903146 1.61 0.052
rs12255372 rs12255372 + rs11196205 0.77 0.219
Stepwise logistic regression analysis to determine whether SNPs at TCF7L2
contribute separate main effects. A significant test comparing null and
alternative models indicates that the marker added under the alternative
model is contributing a separate main effect from the marker considered
under the null hypothesis. Bold indicates nominal P < 0.05
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